Hand‑ Foot Syndrome after Administration of Tyrosinkinase Inhibitors

Česká verzia

Authors: D. Bednaříková ¹; I. Kocák ²
Authors place of work: Privátní kožní ambulance, Brno ¹; Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF MU, Brno ²
Published in the journal: Klin Onkol 2010; 23(5): 300-305
Category: Reviews

Summary

At present, the dermal toxicity of anti‑cancer drugs is ever more apparent in cancer patients. This phenomenon appears, in particular, in relation to the increased administration of targeted anti‑cancer treatment, especially of monoclonal antibodies and tyrosinkinase inhibitors (TKI), towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumour cell. Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand‑ foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib. Developed HFSR may be a strongly perceived adverse effect for patients and may lead to dose intensity reduction in the targeted treatment, or to its interruption if necessary. However, a correct approach from the oncologist and dermatologist, including instructions to be provided to the patient on how to prevent a serious grade of HFSR from being developed, may ensure a smooth anti‑cancer treatment and a satisfactory quality of life for cancer patients.

Key words:
targeted therapy – tyrosinkinase inhibitor – sorafenib – sunitinib – skin – toxicity – hand- foot syndrome

Zdroje

1. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148(2): 90– 92.

2. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368(9544): 1329– 1338.

3. Baack BR, Burgdorf WH. Chemotherapy‑induced acral erythema. J Am Acad Dermatol 1991; 24(3): 457– 461.

4. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19(11): 1955– 1961.

5. Yang CH, Lin WC, Chuang CK et al. Hand‑ foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158(3): 592– 596.

6. Chu D, Lacouture ME, Fillos T et al. Risk of hand‑ foot skin reaction with sorafenib: a systematic review and meta‑analysis. Acta Oncol 2008; 47(2): 176– 186.

7. Chu D, Lacouture ME, Weiner E et al. Risk of hand‑ foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non‑renal cell carcinoma: a meta‑analysis. Clin Genitourin Cancer 2009; 7(1): 11– 19.

8. Autier J, Escudier B, Wechsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144(7): 886– 892.

9. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy‑induced palmar plantar erythrodysesthesia (‘hand‑ foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1(4): 225– 234.

10. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v 4.03: June 14, 2010). Available from: http:/ / evs.nci.nih.gov/ ftp1/ CTCAE/ CTCAE_4.03_2010– 06– 14_QuickReference_8.5x11.pdf.

11. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand‑ foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13(9): 1001– 1011.

12. Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161(5): 1045– 1051.

13. Beldner M, Jacobson M, Burges GE et al. Localized palmar‑ plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007; 12(10): 1178– 1182.

14. Lai SE, Kuzel T, Lacouture ME. Hand‑ foot and stump syndrome to sorafenib. J Clin Oncol 2007; 25(3): 341– 343.

15. Thompson DS, Greco FA, Spigel DR et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. J Clin Oncol 2006; 24 (Suppl 18): 4594.

16. Yang CH, Chuang CK, Hsieh JJ et al. Targeted therapy and hand‑ foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 2010; 9(3): 459– 470.

17. Robert C, Mateus C, Spatz A et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60(2): 299– 305.

18. Robert C, Escudier B. Cutaneous side effects of multikinase inhibitors used in renal cell cancer. Oncology News International 2007; 5: 1– 20.

19. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12(4): 426– 437.

20. Azad NS, Aragon‑ Ching JB, Dahut WL et al. Hand‑ foot skin reaction increases with cumulative sorafenib dose and with combination anti‑vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15(4): 1411– 1416.

21. Jain L, Gardner ER, Figg WD et al. Lack of association between excretion of sorafenib in sweat and hand‑ foot skin reaction. Pharmacotherapy 2010; 30(1): 52– 56.

22. Meta‑Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16(11): 3537– 3541.

23. Keohan M, D’Adamo D, Qin L et al. Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). J Clin Oncol 2007; 25(Suppl 18): 10061.

24. Kampmann KK, Graves T, Rogers SD. Acral erythema secondary to high‑dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 1989; 63(12): 2482– 2485.

25. Abou‑ Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24(26): 4293– 4300.

26. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia‑ Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‑blind, placebo‑ controlled trial. Lancet Oncol 2009; 10(1): 25– 34.

27. Jain L, Sissung TM, Danesi R et al. Hypertension and hand‑ foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010; 29: 95.

28. Vincenzi B, Santini D, Russo A et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15(1): 85– 92.

29. Gressett SM, Stanford BL, Hardwicke F. Management of hand‑ food syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12(3): 131– 141.

30. Lee S, Lee S, Chun Y et al. Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double‑blind placebo‑ controlled study. J Clin Oncol 2007; 25: 9007.

31. Mortimer JE, Lauman M, Tan B et al. Pyridoxine treatment and prevention of hand‑ and‑ foot syndrome in patients receiving capecitabine. J Oncol Pharm Practice 2003; 9: 161– 166.

32. Holečková P. Studie PRESSO 1. Prevence hand – foot skin reaction = kožní reakce na dlaních a chodidlech při terapii Nexavarem (sorafenibem) a korelace stupně hand – foot skin reaction a hladiny neopterinu. Multicentrická randomizovaná nezaslepená prospektivní studie. Data u autorky.